Key statistics dashboard for Actuate Therapeutics Inc (ACTU). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer.
Stock Data
| Price | $1.00 |
| Market Cap | $24M |
| Beta | 0.86 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -1.11 |
| Price / Book | 23.74 |
| P/S | 0.00 |
| P/FCF | -1.19 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 1.25 |
| Quick Ratio | 1.25 |
| Cash Ratio | 1.16 |
| Debt / Equity | 0.41 |
| Debt / Assets | 7.79% |
| Interest Coverage | -1025.81 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -7.40 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 0.04 |
| Cash per share | 0.19 |
| FCF per share | -0.83 |
| Tangible Book Value per share | 0.04 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 1 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 1 |
| Avg rating (1-5) | 1.00 |
Related companies: ALEC · APLT · ELTX · MCRB · MOLN · NKTX · PEPG
Explore sector: Healthcare · Biotechnology
More sections of ACTU: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks